Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-343533
Filing Date
2026-08-11
Accepted
2026-08-11 08:37:50
Documents
80
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mreo-20260630.htm   iXBRL 10-Q 2219785
2 EX-31.1 mreo-ex31_1.htm EX-31.1 26657
3 EX-31.2 mreo-ex31_2.htm EX-31.2 26398
4 EX-32.1 mreo-ex32_1.htm EX-32.1 9250
5 EX-32.2 mreo-ex32_2.htm EX-32.2 8985
  Complete submission text file 0001193125-26-343533.txt   9711118

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20260630.xsd EX-101.SCH 1419937
84 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20260630_htm.xml XML 1868498
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON United Kingdom W1G 0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON United Kingdom W1G 0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38452 | Film No.: 261260767
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)